Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study
Journal of Hospital Infection · 2024
DOI: 10.1016/j.jhin.2024.06.004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Hospital Infection, 2024. Verfasst von T Zheng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Surgical Wound Infection, Nitroimidazoles. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program.
Abstract (Originalsprache)
INTRODUCTION: Surgical site infections (SSIs) are significant postoperative risks; antibiotic prophylaxis is crucial due to the presence of anaerobic bacteria. This study investigated the efficacy and safety of a novel nitroimidazole, morinidazole, in SSI reduction in class III wounds, as there is currently a lack of evidence in the existing literature. METHODS: A multi-centre randomized clinical trial was conducted from December 2020 to October 2022 in the general surgery departments of 12 tertiary hospitals in China, including 459 patients in two treatment groups using morinidazole plus ceftriaxone or ceftriaxone alone. Efficacy and safety were evaluated including SSI incidence, adverse events, and compliance. Statistical analysis employed SAS 9.4 software. Data analysis was performed from February to May 2023. RESULTS: A total of 440 participants (median (interquartile range, IQR) age, 63.0 (54.0, 70.0) years; 282 males (64.09%); 437 patients were of Han race (99.32%) and were randomized. The experimental group exhibited a significantly lower SSI rate compared with the control group (31 (14.49%) vs 52 (23.01%); risk difference, 1.76%, 95% confidence interval (CI) 1.08-2.88%; P=0.0224). The superficial incisional site infections revealed a marked reduction in the experimental group (12 (5.61%) vs 31 (13.37%); risk difference, 2.68%; 95% CI 1.34-5.36%; P=0.0042). Non-surgical site infections, severe postoperative complications, and total adverse events showed no statistically significant differences between the groups (P>0.05). CONCLUSION: The significant decrease in SSI rates and superficial incisional infections demonstrates morinidazole to be a valuable prophylactic antibiotic. Our findings provide valuable insights for clinical practice, where this new-generation nitroimidazole can play a crucial role in SSI prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China.
- Department of Emergency Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Gastrointestinal Surgery, The People's Hospital of Maanshan, Maanshan, China.
- Department of General Surgery, The First People's Hospital of Zhenjiang, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Förderung
- Jiangsu Provincial Key Research and Development Program
Zitieren
APA
Zheng, T., Wang, R., Wu, C., Li, S., Cao, G., Zhang, Y., Bu, X., Jiang, J., Kong, Z., Miao, Y., Zheng, L., Tao, G., Tao, Q., Ding, Z., Wang, P., & Ren, J. (2024). Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study. Journal of Hospital Infection. https://doi.org/10.1016/j.jhin.2024.06.004
Vancouver
Zheng T, Wang R, Wu C, Li S, Cao G, Zhang Y, et al. Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study. Journal of Hospital Infection. 2024. doi:10.1016/j.jhin.2024.06.004
BibTeX
@article{Zheng2024,
author = {Zheng, T and Wang, R and Wu, C and Li, S and Cao, G and Zhang, Y and Bu, X and Jiang, J and Kong, Z and Miao, Y and Zheng, L and Tao, G and Tao, Q and Ding, Z and Wang, P and Ren, J},
title = {Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study},
journal = {Journal of Hospital Infection},
year = {2024},
doi = {10.1016/j.jhin.2024.06.004}
}
EUVIMED